Pomp combination chemotherapy of adult acute leukemia.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001853:Bone Marrow / Q000187:drug effects; D004064:Digestive System / Q000187:drug effects; D005069:Evaluation Studies as Topic; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008099:Liver / Q000187:drug effects; D015122:Mercaptopurine / Q000627:therapeutic use*; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D010292:Paresthesia / Q000139:chemically induced; D011241:Prednisone / Q000627:therapeutic use*; D011379:Prognosis; D012075:Remission, Spontaneous; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014750:Vincristine; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate